Business Weekly has published its 2019 list of Cambridge’s most disruptive tech and life science companies, known as the ‘Killer50’.
More than half of this year’s list are life science innovators. And five of those are based at Chesterford Research Park.
Park Manager Katherine Maguire said: “We’re thrilled to see so many Chesterford-based companies recognised in this year’s list.
“The Park is home to companies that are making a real difference. Scientists, investors and entrepreneurs work side by side at the Park, developing life-changing drugs amongst an innovative community.
“We see the hard work and dedication from our tenants on a day-to-day basis and we’re proud to help facilitate their ground-breaking science and help promote their achievements.”
And here they are:
Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.
CellCentric is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for prostate (CRPC) and other cancers. It originally span out of the University of Cambridge, drawing on the work of one of the pioneers of epigenetics, Prof Azim Surani FRS CBE. The company’s leadership has deep R&D experience gained in academia, large pharma and biotechs, spanning from basic biological research through to international clinical development programmes.
Founded in 2012 by Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing which underpins the market-leading Illumina®sequencing technology, and Dr Bobby Yerramilli-Rao, Cambridge Epigenetix is pioneering the epigenetics revolution. Its mission is to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification.
Evonetix is set to revolutionise de novo gene synthesis to facilitate the fast-growing and exciting field of synthetic biology. Its technology is based upon a novel silicon array, manufactured with semiconductor microfabrication techniques and capable of independent control of 10,000 miniaturised reaction sites, allowing massive parallelism in the DNA synthesis process and therefore very high throughput. It will have a fundamental impact on science and industry, and potentially on the quality of life for millions of individuals.
NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases driven by chronic inflammation. NodThera was seed funded by Epidarex Capital based on research from Selvita. NodThera is initially targeting the NLRP3 inflammasome with small molecule inhibitors and is building a pipeline of NLRP3 inflammasome inhibitors through a highly differentiated, next generation approach that builds on and enhances existing understanding of NLRP3 biochemistry and its role in inflammation.